Skip Navigation


JAC Advance Access originally published online on October 16, 2003
This Article
Right arrow Full Text Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow All Versions of this Article:
52/5/743    most recent
dkg454v1
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Search for citing articles in:
ISI Web of Science (4)
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Bogaards, J. A.
Right arrow Articles by Goudsmit, J.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Bogaards, J. A.
Right arrow Articles by Goudsmit, J.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?


Journal of Antimicrobial Chemotherapy (2003) 52, 743-746
© 2003 The British Society for Antimicrobial Chemotherapy

Leading Article

Meeting the immense need for HAART in resource-poor settings

Johannes A. Bogaards1,2,* and Jaap Goudsmit3,5

Departments of 1 Human Retrovirology, 2 Clinical Epidemiology and Biostatistics and 3 Internal Medicine, Division of Infectious Diseases, Tropical Medicine and AIDS, Academic Medical Center, University of Amsterdam, Amsterdam; 4 Center for Poverty-related Communicable Diseases, Amsterdam; 5 Crucell, Leiden, The Netherlands

Keywords: HIV, antiretroviral therapy, developing world

The first 150 words of the full text of this article appear below.

According to recent estimates, 42 million people worldwide suffer from infection with HIV, the causative agent of AIDS.1 Less than 5% of these live in high-income countries where highly active antiretroviral therapy (HAART) is widely available. Falling prices of antiretroviral drugs and increasing donor support from affluent countries should enable a larger portion of the world’s HIV-infected population to gain access to HAART, but public health organizations are being relatively slow, maybe even hesitant, about its large-scale implementation. This relates primarily to concerns regarding feasibility and sustainability of HAART in resource-poor settings. Clinical opinion leaders start from the underlying assumption that HAART is only effective when it is administered under guidance of laboratory markers. Here, we present the view that laboratory marker guidance might increase the efficiency of HAART, but at the same time slows down access to treatment in countries that lack a clinical and laboratory infrastructure.

Internationally accepted . . . [Full Text of this Article]


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
 Health Policy PlanHome page
S. Tantivess and G. Walt
The role of state and non-state actors in the policy process: the contribution of policy networks to the scale-up of antiretroviral therapy in Thailand
Health Policy Plan., September 1, 2008; 23(5): 328 - 338.
[Abstract] [Full Text] [PDF]